The Medtronic APOLLO Clinical Trial is evaluating the safety and efficacy of an investigative device called the Intrepid Transcatheter Mitral Valve Replacement System (TMVR) for moderate-to-severe or severe symptomatic mitral regurgitation (MR) in patients who may be unsuitable for approved transcatheter repair or surgery.
News | Structural Heart
Hackensack Meridian Jersey Shore University Medical Center Providing State-of-the-Art Medtronic APOLLO Clinical Trial Treating Heart Valve Disease

February 20, 2024 — As New Jersey’s leading provider of high-quality cardiac procedures and diagnostic testing and an ...

Home February 20, 2024
Home
Ultrahigh-spatial-resolution photon-counting detector CT improved assessment of coronary artery disease (CAD), allowing for reclassification to a lower disease category in 54% of patients
News | Computed Tomography (CT)
Photon-Counting CT Improves Coronary Artery Disease Assessment

February 20, 2024 — Ultrahigh-spatial-resolution photon-counting detector CT improved assessment of coronary artery ...

Home February 20, 2024
Home
The study, titled "Targeted Therapy with Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy" (TaRGET), will be led by the research team at PHRI and will involve collaboration with multiple organizations in addition to AMO Pharma including the Hearts in Rhythm Organization (HiRO). 
News | Pharmaceuticals
AMO Pharma Announces Collaboration with Population Health Research Institute to Advance Proof of Concept Clinical Trial to Assess Efficacy of Tideglusib in Treatment of Arrhythmogenic Cardiomyopathy

February 16, 2024 — AMO Pharma Limited, a privately held clinical-stage specialty biopharmaceutical company focusing on ...

Home February 16, 2024
Home
Transformative cardiovascular risk management solutions extend beyond traditional sectors to include federal and state correctional facilities, broker and benefits organizations, and risk bearing providers
News | Artificial Intelligence
Cardio Diagnostics Holdings, Inc. Expands HeartRisk Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout

February 16, 2024 — Cardio Diagnostics Holdings, Inc., an AI-driven precision cardiovascular medicine company, announced ...

Home February 16, 2024
Home
Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a subsidiary of Bayer AG, have announced that the first patient has been randomized in GenePHIT (Gene PHosphatase Inhibition Therapy), a Phase II trial of AB-1002, also known as NAN-101, for the treatment of congestive heart failure (CHF).
News | Cardiovascular Clinical Studies
First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure Treatment

February 15, 2024 — Bayer AG and Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and ...

Home February 15, 2024
Home
Research findings in a clinical trial led by a professor at the University of Tennessee Health Science Center’s College of Nursing are likely to dramatically change care and improve outcomes for patients suffering from acute stroke.
News | Stroke
ZODIAC Clinical Trial Led by UT Health Science Center Professor Likely to Make Major Impact on Stroke Care

February 15, 2024 — Research findings in a clinical trial led by a professor at the University of Tennessee Health ...

Home February 15, 2024
Home
The limited clinical trial represents the first human implantation of a cardiac auscultation sensor device
News | Heart Failure
Canary Completes First-in-Human Trial of Cardiac Auscultation Monitoring Sensor

February 15, 2024 — Canary Medical, a medical data company focused on the development and commercialization of its ...

Home February 15, 2024
Home
Panel of independent experts reviewed data from the TRILUMINATE pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip system
News | Structural Heart
FDA Advisory Committee Votes in Favor of Abbott’s First-of-its-kind Triclip System to Treat People with a Leaky Tricuspid Heart Valve

February 15, 2024 — Abbott announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee ...

Home February 15, 2024
Home
NCDR’s CV ASC Registry Suite follows increases in ambulatory cardiac procedures, provides benchmarks
News | ACC
First-of-its-kind ACC Registry Tracks Cardiac Procedures Performed in Ambulatory Surgical Settings

February 14, 2024 — The American College of Cardiology’s newest registry offers data-driven insights on cardiac ...

Home February 14, 2024
Home
Novel bioresorbable scaffold system being developed for expanded indications
News | Stents Bioresorbable
AI Measures Fat Around the Heart, a Key to Predicting Heart Attacks

February 14, 2024 — Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced that ...

Home February 14, 2024
Home
The replacement of regular salt with a salt substitute can reduce incidences of hypertension, or high blood pressure, in older adults without increasing their risk of low blood pressure episodes, according to a study published in the Feb. 2024 issue of the Journal of the American College of Cardiology (JACC).
News | Hypertension
DECIDE-Salt Study Finds Salt Substitutes Help to Maintain Healthy Blood Pressure in Older Adults

February 14, 2024 — The replacement of regular salt with a salt substitute can reduce incidences of hypertension, or ...

Home February 14, 2024
Home
In a groundbreaking study, researchers from The Texas Heart Institute, Baylor College of Medicine, Texas Children's Hospital, and the University of Texas Health Science Center McGovern Medical School have shed light on the underlying molecular cell states within transplanted pediatric hearts, paving the way for improved treatment strategies and enhancing the longevity of cardiac allografts.
News | Pediatric Cardiology
Revolutionary Genomic Study Sheds Light on Immune Microenvironment in Transplanted Pediatric Hearts

February 13, 2024 — Pediatric heart transplantation has long been hailed as a life-saving intervention for children ...

Home February 13, 2024
Home
The company’s roster of clinical evidence continues to grow, with data highlights on expediting, broadening, and challenging current guidelines in stroke care
News | Stroke
RapidAI Announces Late-Breaking Abstract Simultaneously Published in NEJM; Highlights Key Data Revealed at ISC 2024

February 13, 2024 — RapidAI, the global leader in developing Artificial Intelligence (AI) and clinical workflow ...

Home February 13, 2024
Home
Butterfly iQ3 is built on the next-generation P4.3 Ultrasound-on-Chip technology with the world’s fastest digital data transfer, enhancing frame rates, frequency and new 3D imaging capabilities – all on a smaller, lighter and more ergonomically designed probe
News | Point-of-Care Ultrasound (POCUS)
Butterfly Network Launches Next-Generation Butterfly iQ3 in the United States

February 13, 2024 — Butterfly Network, Inc., a digital health company transforming care through the power of portable ...

Home February 13, 2024
Home
Cleerly has announced continued strong scientific evidence supporting the clinical utility of its products, detailing a study published online on Jan. 25, 2024 in the European Heart Journal Cardiovascular Imaging
News | Artificial Intelligence
Results of CERTAIN Study Demonstrate Prominent Effects of Cleerly Products on Changing Clinical Management for Patients Suspected of Coronary Artery Disease

February 13, 2024 — Cleerly, a digital healthcare company focused on artificial intelligence (AI)-driven heart disease ...

Home February 13, 2024
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now